136 related articles for article (PubMed ID: 32519194)
1. Prevalence and sort of pharmacokinetic drug-drug interactions in hospitalized psychiatric patients.
Hefner G; Wolff J; Hahn M; Hiemke C; Toto S; Roll SC; Messer T; Klimke A
J Neural Transm (Vienna); 2020 Aug; 127(8):1185-1198. PubMed ID: 32519194
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
Preskorn SH
J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.
Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A
J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.
Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD
J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306
[TBL] [Abstract][Full Text] [Related]
6. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
Tornio A; Filppula AM; Backman JT
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044
[TBL] [Abstract][Full Text] [Related]
7. Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.
Schoretsanitis G; de Leon J; Eap CB; Kane JM; Paulzen M
CNS Drugs; 2019 Dec; 33(12):1201-1222. PubMed ID: 31776871
[TBL] [Abstract][Full Text] [Related]
8. A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach.
Wang L; Shendre A; Chiang CW; Cao W; Ning X; Zhang P; Zhang P; Li L
Br J Clin Pharmacol; 2022 Feb; 88(4):1471-1481. PubMed ID: 33543792
[TBL] [Abstract][Full Text] [Related]
9. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
11. Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients.
Toto S; Hefner G; Hahn M; Hiemke C; Roll SC; Wolff J; Klimke A
J Neural Transm (Vienna); 2021 Feb; 128(2):263-272. PubMed ID: 33439364
[TBL] [Abstract][Full Text] [Related]
12. Potentially inappropriate medication in older psychiatric patients.
Hefner G; Hahn M; Toto S; Hiemke C; Roll SC; Wolff J; Klimke A
Eur J Clin Pharmacol; 2021 Mar; 77(3):331-339. PubMed ID: 33029652
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant drug interactions between statins and antidepressants.
Palleria C; Roberti R; Iannone LF; Tallarico M; Barbieri MA; Vero A; Manti A; De Sarro G; Spina E; Russo E
J Clin Pharm Ther; 2020 Apr; 45(2):227-239. PubMed ID: 31587356
[TBL] [Abstract][Full Text] [Related]
14. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence-Based High-Throughput Assays for Investigating Cytochrome P450 Enzyme-Mediated Drug-Drug Interactions.
He R; Dai Z; Finel M; Zhang F; Tu D; Yang L; Ge G
Drug Metab Dispos; 2023 Oct; 51(10):1254-1272. PubMed ID: 37349113
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Interactions Between Antiseizure and Psychiatric Medications.
Zaccara G; Franco V
Curr Neuropharmacol; 2023; 21(8):1666-1690. PubMed ID: 35611779
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.
Nettleton DO; Einolf HJ
Curr Top Med Chem; 2011; 11(4):382-403. PubMed ID: 21320066
[TBL] [Abstract][Full Text] [Related]
18. The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.
Mikov M; Đanić M; Pavlović N; Stanimirov B; Goločorbin-Kon S; Stankov K; Al-Salami H
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):881-890. PubMed ID: 28534261
[TBL] [Abstract][Full Text] [Related]
19. A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment.
Lee J; Beers JL; Geffert RM; Jackson KD
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254699
[TBL] [Abstract][Full Text] [Related]
20. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
